225 related articles for article (PubMed ID: 33499047)
1. Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells.
El Hallal R; Lyu N; Wang Y
Molecules; 2021 Jan; 26(3):. PubMed ID: 33499047
[TBL] [Abstract][Full Text] [Related]
2. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer.
Okada Y; Kimura T; Nakagawa T; Okamoto K; Fukuya A; Goji T; Fujimoto S; Sogabe M; Miyamoto H; Muguruma N; Tsuji Y; Okahisa T; Takayama T
Mol Cancer Res; 2017 Oct; 15(10):1445-1454. PubMed ID: 28698359
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
[TBL] [Abstract][Full Text] [Related]
4. Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells.
Mitra M; Kandalam M; Rangasamy J; Shankar B; Maheswari UK; Swaminathan S; Krishnakumar S
Mol Vis; 2013; 19():1029-38. PubMed ID: 23687439
[TBL] [Abstract][Full Text] [Related]
5. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA
Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896
[TBL] [Abstract][Full Text] [Related]
6. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
Veluchamy JP; Spanholtz J; Tordoir M; Thijssen VL; Heideman DA; Verheul HM; de Gruijl TD; van der Vliet HJ
PLoS One; 2016; 11(6):e0157830. PubMed ID: 27314237
[TBL] [Abstract][Full Text] [Related]
7. Gold nanoparticles affect the antioxidant status in selected normal human cells.
Daems N; Penninckx S; Nelissen I; Van Hoecke K; Cardinaels T; Baatout S; Michiels C; Lucas S; Aerts A
Int J Nanomedicine; 2019; 14():4991-5015. PubMed ID: 31371943
[No Abstract] [Full Text] [Related]
8. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
9. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
10. Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice.
Karmani L; Labar D; Valembois V; Bouchat V; Nagaswaran PG; Bol A; Gillart J; Levêque P; Bouzin C; Bonifazi D; Michiels C; Feron O; Grégoire V; Lucas S; Vander Borght T; Gallez B
Contrast Media Mol Imaging; 2013; 8(5):402-8. PubMed ID: 23740810
[TBL] [Abstract][Full Text] [Related]
11. Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model.
Kao HW; Lin YY; Chen CC; Chi KH; Tien DC; Hsia CC; Lin WJ; Chen FD; Lin MH; Wang HE
Nanotechnology; 2014 Jul; 25(29):295102. PubMed ID: 24990295
[TBL] [Abstract][Full Text] [Related]
12. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
13. Gold Nanoparticles Enhance EGFR Inhibition and Irradiation Effects in Head and Neck Squamous Carcinoma Cells.
Kashin M; Kakei Y; Teraoka S; Hasegawa T; Yamaguchi A; Fukuoka T; Sasaki R; Akashi M
Biomed Res Int; 2020; 2020():1281645. PubMed ID: 33204681
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
15. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.
Khelwatty S; Essapen S; Bagwan I; Green M; Seddon A; Modjtahedi H
Oncotarget; 2017 Jan; 8(5):7666-7677. PubMed ID: 28032593
[TBL] [Abstract][Full Text] [Related]
16. Where now for anti-EGF receptor therapies in colorectal cancer?
Shaw PH; Adams RA
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1543-53. PubMed ID: 21999128
[TBL] [Abstract][Full Text] [Related]
17. Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
Chen SH; Tsai HL; Jiang JK; Sung YC; Huang CW; Yeh YM; Chen LT; Wang JY
BMC Cancer; 2019 Jun; 19(1):640. PubMed ID: 31253124
[TBL] [Abstract][Full Text] [Related]
18. Characterising the phenotypic evolution of circulating tumour cells during treatment.
Tsao SC; Wang J; Wang Y; Behren A; Cebon J; Trau M
Nat Commun; 2018 Apr; 9(1):1482. PubMed ID: 29662054
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
[TBL] [Abstract][Full Text] [Related]
20. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.
Wu Z; Huang M; Gong Y; Lin C; Guo W
Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):355-361. PubMed ID: 29534162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
